Urology eLearning Workshop; A guide to NMIBC - Module 5 Mitomycin C and BCG side effects; contraindications and precautions

Online Course • medac Pharma

About the CPD course

This is the fifth module of an eLearning course which features 6 interactive modules; covering a full range of topics within non-muscle invasive bladder cancer. When you have completed this module; you should be able to; Outline key information that patients should receive about intravesical Mitomycin C (MMC) and intravesical Bacillus Calmette-Guérin; (BCG) for NMIBC; Describe the most common side effects of these two agents; Name some steps that can help patients manage side effects and complete their treatment; Describe the contraindications for MMC and BCG intravesical therapies; Describe precautions to consider for patients receiving these treatments.

CPD Provider

medac Pharma

View Profile

Send an enquiry

Full Name*

Email Address*

Contact Number*

Industry*

Your Enquiry*

By submitting this form, you consent to CPD sending you email regarding your application.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

medac Pharma

medac Pharma is a privately owned, pharmaceutical company specialising in the development, diagnosis and treatment of diseases within the key areas of oncology, urology, haematology and autoimmune. The company was originally founded in Germany in 1970 and the UK operation was established in 1993. Since then we have become known for developing innovative products from standard cancer chemotherapy to niche speciality medicines.